Goldman Sachs Upgrades Celanese (CE) to Buy, Sees 32% Upside
Get Alerts CE Hot Sheet
Price: $45.66 +3.07%
Rating Summary:
15 Buy, 12 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
15 Buy, 12 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs upgraded Celanese (NYSE: CE) from Neutral to Buy, with a $62 price target suggesting 32% upside.
The upgrade comes ahead of its May 10 investor day and following recent meetings with management, very strong 1Q11 results and forward outlook, and recent stock weakness.
The firm sees 2011/12/13 EPS of $4.56/$5.31/$6.17 versus prior $4.04/$4.7 /$5.50.
Goldman views May 10 analyst day as a catalyst and views the company "as one of the best beat and raise stories in our coverage universe and we are currently 7% / 9% above consensus' 2011/12 EPS estimates."
For more ratings news on Celanese click here and for the rating history of Celanese click here.
Shares of Celanese closed at $47.12 yesterday.
The upgrade comes ahead of its May 10 investor day and following recent meetings with management, very strong 1Q11 results and forward outlook, and recent stock weakness.
The firm sees 2011/12/13 EPS of $4.56/$5.31/$6.17 versus prior $4.04/$4.7 /$5.50.
Goldman views May 10 analyst day as a catalyst and views the company "as one of the best beat and raise stories in our coverage universe and we are currently 7% / 9% above consensus' 2011/12 EPS estimates."
For more ratings news on Celanese click here and for the rating history of Celanese click here.
Shares of Celanese closed at $47.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Street Research Upgrades Micron Technology (MU) to Buy
- Canaccord Upgrades HLS Therapeutics (HLS:CN) (HLTRF) to Buy
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share